Agile incurs higher net loss of USD5.2m for Q4 2016.
M2 PHARMA-March 9, 2017-Agile incurs higher net loss of USD5.2m for Q4 2016
(C)2017 M2 COMMUNICATIONS
Pharmaceutical company Agile Therapeutics Inc (NasdaqGM:AGRX) stated on Wednesday that it recorded a net loss of USD5.2m (USD0.18 per basic share) for the three months ended 31 December 2016.
This marks a fall in earnings when compared with a net loss of USD3.9m (USD0.17 per basic share) for the quarter ended 31 December 2015.
R&D expenses of USD5.5m were recorded for the quarter ended 31 December 2016, a decline over USD6.9m for the comparable period in 2015, which was primarily due to decreased clinical development expenses as its Phase 3 clinical trial for Twirla moved closer to completion.
As of 31 December 2016, the company announced USD48.8m of cash and cash equivalents, a rise versus USD34.4m of cash and cash equivalents as of 31 December 2015.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Mar 9, 2017|
|Previous Article:||Patient Education Improves Colonoscopy Preparation; May Reduce Need for Repeat Screenings, Study Finds.|
|Next Article:||Allergan files sNDA with the US FDA for VRAYLAR treatment for schizophrenia in adults.|